Ontology highlight
ABSTRACT: Background
Idiopathic pulmonary fibrosis (IPF) is a rare life-threating interstitial lung disease (ILD). This study characterizes demographics, health care utilization, and comorbidities among elderly IPF patients and estimates prevalence and incidence rates for selected outcomes.Methods
Cohort study using a large US health insurance database (Optum's Medicare Advantage plan).Inclusion criteria
? 1 diagnosis code for IPF (2008 - 2014), age ?65 years, no diagnosis of IPF or other ILD in prior 12 months. Demographics, health care utilization, comorbidities and incidence rates for various outcomes were estimated. Follow-up continued until the earliest of: health plan disenrollment, death, a claim for another known cause of ILD, or end of the study period.Results
4,716 patients were eligible; 53.4% had IPF diagnostic testing. Median age was 77.5 years, 50.3% were male, median follow-up time was 0.8 years. Incidence rates ranged from 1.0/1,000 person-years (lung transplantation) to 374.3/1,000 person-years (arterial hypertension). Baseline characteristics and incidence rates were similar for cohorts of patients with and without IPF diagnostic testing.Conclusions
Elderly IPF patients experience a variety of comorbidities before and after IPF diagnosis. Therapies for IPF and for the associated comorbidities may reduce morbidity and associated health care utilization of these patients.
SUBMITTER: Mortimer K
PROVIDER: S-EPMC6327584 | biostudies-literature | 2019 Jan
REPOSITORIES: biostudies-literature
BMC pulmonary medicine 20190110 1
<h4>Background</h4>Idiopathic pulmonary fibrosis (IPF) is a rare life-threating interstitial lung disease (ILD). This study characterizes demographics, health care utilization, and comorbidities among elderly IPF patients and estimates prevalence and incidence rates for selected outcomes.<h4>Methods</h4>Cohort study using a large US health insurance database (Optum's Medicare Advantage plan).<h4>Inclusion criteria</h4>≥ 1 diagnosis code for IPF (2008 - 2014), age ≥65 years, no diagnosis of IPF o ...[more]